Next Article in Journal
Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)–Never Change a Running System?
Next Article in Special Issue
Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
Previous Article in Journal / Special Issue
The Impact of SARS-CoV-2 Infection, and Application of Immunosuppressive Agents in Kidney Transplant Recipients Suffering from COVID-19
 
 
Article

Article Versions Notes

Pharmaceuticals 2021, 14(10), 1055; https://doi.org/10.3390/ph14101055
Action Date Notes Link
article pdf uploaded. 17 October 2021 16:06 CEST Version of Record https://www.mdpi.com/1424-8247/14/10/1055/pdf-vor
article supplementary file uploaded. 17 October 2021 16:06 CEST - https://www.mdpi.com/1424-8247/14/10/1055#supplementary
article xml file uploaded 19 October 2021 10:45 CEST Original file -
article xml uploaded. 19 October 2021 10:45 CEST Update -
article pdf uploaded. 19 October 2021 10:45 CEST Updated version of record https://www.mdpi.com/1424-8247/14/10/1055/pdf-vor
article html file updated 19 October 2021 10:47 CEST Original file -
article xml file uploaded 20 October 2021 11:15 CEST Update -
article xml uploaded. 20 October 2021 11:15 CEST Update -
article pdf uploaded. 20 October 2021 11:15 CEST Updated version of record https://www.mdpi.com/1424-8247/14/10/1055/pdf-vor
article html file updated 20 October 2021 11:17 CEST Update -
article xml file uploaded 21 October 2021 02:49 CEST Update -
article xml uploaded. 21 October 2021 02:49 CEST Update https://www.mdpi.com/1424-8247/14/10/1055/xml
article pdf uploaded. 21 October 2021 02:49 CEST Updated version of record https://www.mdpi.com/1424-8247/14/10/1055/pdf
article html file updated 21 October 2021 02:51 CEST Update -
article html file updated 30 July 2022 11:28 CEST Update https://www.mdpi.com/1424-8247/14/10/1055/html
Back to TopTop